AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7419011 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal fat (20 g of Intralipid)
Number of subjects: 5
Study 7419011 — intervention group
Group type: COMPARATOR
Intervention: Intravenous amino acids (21 g L‐amino acids; Freamine II) plus glucose (50 g)
Number of subjects: 5
Study 30776476 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (1800 mg containing 1206 mg EPA) for 12 weeks
Number of subjects: 108
Study 30776476 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 108
Study 30640652 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of perineural dexamethasone
Number of subjects: 360
Study 30640652 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of perineural dexamethasone
Number of subjects: 360
Study 30640652 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of perineural dexamethasone
Number of subjects: 360
Study 30640652 — intervention group
Group type: COMPARATOR
Intervention: Control (no dexamethasone)
Number of subjects: 360
Study 28673322 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with donepezil
Number of subjects: 334
Study 28673322 — intervention group
Group type: COMPARATOR
Intervention: Donepezil
Number of subjects: 334
Study 26419363 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4000 IE/day for 1 year)
Number of subjects: 124
Study 26419363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 23524017 — intervention group
Group type: EXPERIMENTAL
Intervention: Supratherapeutic doses of salbutamol (SALB) 200 μg (3 doses at 20 min intervals)
Number of subjects: 44
Study 23524017 — intervention group
Group type: EXPERIMENTAL
Intervention: Supratherapeutic doses of ipratropium bromide (IPR) 20 μg, 20 μg, and 40 μg (at 20 min intervals)
Number of subjects: 44
Study 23524017 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 44
Study 23524017 — intervention group
Group type: EXPERIMENTAL
Intervention: Supratherapeutic doses of salbutamol (SALB) 200 μg (3 doses at 20 min intervals) after MABA 1200
Number of subjects: 44
Study 23524017 — intervention group
Group type: EXPERIMENTAL
Intervention: Supratherapeutic doses of ipratropium bromide (IPR) after MABA 1200
Number of subjects: 44
Study 22002970 — intervention group
Group type: EXPERIMENTAL
Intervention: ¡Si, Yo Puedo Controlar Mi Diabetes! diabetes self-management education program
Number of subjects: 144
Study 22002970 — intervention group
Group type: COMPARATOR
Intervention: Control (wait list)
Number of subjects: 144
Study 19515536 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release MET (500 to 1000 mg daily)
Number of subjects: 61
Study 19515536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 19515536 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release MET
Number of subjects: 61
Study 17597827 — intervention group
Group type: EXPERIMENTAL
Intervention: LED phototherapy
Number of subjects: 66
Study 17597827 — intervention group
Group type: COMPARATOR
Intervention: BB phototherapy
Number of subjects: 66
Study 15524061 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate hemodialysis after PTA
Number of subjects: 66
Study 15524061 — intervention group
Group type: COMPARATOR
Intervention: Next day hemodialysis after PTA
Number of subjects: 66
Study 11499332 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbinafine 250 mg once daily for 2 or 4 weeks
Number of subjects: 27
Study 9643531 — intervention group
Group type: EXPERIMENTAL
Intervention: CDE plus saquinavir (600mg PO TID)
Number of subjects: 12
Study 9643531 — intervention group
Group type: COMPARATOR
Intervention: CDE without saquinavir (from prior study)
Number of subjects: 12
Study 9643531 — intervention group
Group type: EXPERIMENTAL
Intervention: CDE plus saquinavir
Number of subjects: 12
Study 8159103 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol 400 mg x 1
Number of subjects: 42
Study 8159103 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol succinate 200 mg x 1
Number of subjects: 42
Study 29689045 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting group intervention (visits by child development agents and fortnightly meetings)
Number of subjects: 526
Study 29689045 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting group intervention
Number of subjects: 526
Study 28416195 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg
Number of subjects: 252
Study 28416195 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg
Number of subjects: 252
Study 26755466 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-existential group therapy (12 sessions of 90 minutes twice per week)
Number of subjects: 22
Study 22584916 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4-guided planned treatment interruptions (PTIs)
Number of subjects: 109
Study 22584916 — intervention group
Group type: COMPARATOR
Intervention: Continuous therapy (CT)
Number of subjects: 109
Study 21358200 — intervention group
Group type: EXPERIMENTAL
Intervention: Finafloxacin 200 mg
Number of subjects: 6
Study 21358200 — intervention group
Group type: EXPERIMENTAL
Intervention: Finafloxacin 800 mg
Number of subjects: 6
Study 21358200 — intervention group
Group type: EXPERIMENTAL
Intervention: Finafloxacin in acidic urine
Number of subjects: 6
Study 21358200 — intervention group
Group type: EXPERIMENTAL
Intervention: Finafloxacin in alkaline urine
Number of subjects: 6
Study 17574675 — intervention group
Group type: EXPERIMENTAL
Intervention: Submacular surgery
Number of subjects: 690
Study 17574675 — intervention group
Group type: COMPARATOR
Intervention: Ophthalmologist's assessment of lens opacity
Number of subjects: 690
Study 17574675 — intervention group
Group type: COMPARATOR
Intervention: Fundus photograph quality
Number of subjects: 690
Study 17182987 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage with quantitative culture
Number of subjects: 740
Study 17182987 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal aspiration with nonquantitative culture
Number of subjects: 740
Study 14578411 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 12
Study 14578411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10744200 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% mequitazine eyedrops
Number of subjects: 22
Study 10744200 — intervention group
Group type: COMPARATOR
Intervention: 2% disodium cromoglycate eyedrops
Number of subjects: 22
Study 8833554 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA morphine: 1 mg with 6-minute lockout
Number of subjects: 34
Study 8833554 — intervention group
Group type: COMPARATOR
Intervention: PCACI: PCA morphine 1 mg with 6-minute lockout plus 0.5-1 mg/h continuous infusion
Number of subjects: 34
Study 1558438 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline treatment (oral, 7 days, plasma level 87.7 +/‐ 7.8 mumol/L)
Number of subjects: 8
Study 1558438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2859183 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 4
Study 2859183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 29511170 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized LASAG
Number of subjects: 48
Study 29511170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 26846859 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus with Δ≥10.9 HU (n=81, 44%)
Number of subjects: 184
Study 26846859 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus with ε≥6.5% (n=77, 42%)
Number of subjects: 184
Study 26846859 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus perviousness (Δ and ε)
Number of subjects: 184
Study 25141137 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily, amoxicillin 1 g twice daily, esomeprazole 40 mg twice daily)
Number of subjects: 158
Study 25141137 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily, amoxicillin 1 g twice daily, esomeprazole 40 mg twice daily)
Number of subjects: 158
Study 25141137 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily) with levofloxacin-susceptible strains
Number of subjects: 158
Study 25141137 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily) with levofloxacin-resistant strains
Number of subjects: 158
Study 25141137 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily) with levofloxacin-susceptible strains
Number of subjects: 158
Study 25141137 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily) with levofloxacin-resistant strains
Number of subjects: 158
Study 22738608 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrus HD spectral‐domain optical coherence tomography (OCT)
Number of subjects: 36
Study 22738608 — intervention group
Group type: COMPARATOR
Intervention: Control group (70 healthy young subjects, mean age 22.66 years)
Number of subjects: 36
Study 20375351 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention plus usual care
Number of subjects: 62
Study 20375351 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 62
Study 18719005 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational rating of gait variability
Number of subjects: 46
Study 18719005 — intervention group
Group type: COMPARATOR
Intervention: Stance time variability derived from computerized walkway
Number of subjects: 46
Study 16042022 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture naming in Alzheimer's patients using commonly used analyses for single cases (chi2 and z-scores)
Number of subjects: 0
Study 16042022 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture naming in a different group of Alzheimer's patients using the same techniques (chi2 and z-scores)
Number of subjects: 0
Study 16042022 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture naming in the same Alzheimer's patients using stimuli that did not produce ceiling effects/skewed distributions and statistical methods that did not treat the control sample as a population
Number of subjects: 0
Study 16042022 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 11788212 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous followed by oral conjugated estrogen for 21 days
Number of subjects: 293
Study 11788212 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous estrogen followed by oral conjugated estrogen plus medroxyprogesterone for 21 days
Number of subjects: 293
Study 11788212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293
Study 10811511 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA and Strecker-stent (n=15)
Number of subjects: 32
Study 10811511 — intervention group
Group type: COMPARATOR
Intervention: PTA alone (n=17)
Number of subjects: 32
Study 7807041 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0
Study 7807041 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 2111627 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (10 mg)
Number of subjects: 60
Study 2111627 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (100 micrograms)
Number of subjects: 60
Study 6992914 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral paramedian incision
Number of subjects: 207
Study 6992914 — intervention group
Group type: COMPARATOR
Intervention: Midline incision
Number of subjects: 207
Study 6992914 — intervention group
Group type: COMPARATOR
Intervention: Medial paramedian incision
Number of subjects: 207
Study 31416459 — intervention group
Group type: EXPERIMENTAL
Intervention: Umoyo clinics
Number of subjects: 28
Study 31416459 — intervention group
Group type: COMPARATOR
Intervention: Control facilities
Number of subjects: 28
Study 28522452 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy (APM)
Number of subjects: 146
Study 28522452 — intervention group
Group type: COMPARATOR
Intervention: Placebo surgery
Number of subjects: 146
Study 27466224 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mL Hyaluronic Acid (HA) injection
Number of subjects: 60
Study 27466224 — intervention group
Group type: COMPARATOR
Intervention: 3 mL saline solution (placebo)
Number of subjects: 60
Study 24401765 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine 5 mg
Number of subjects: 12
Study 24401765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23138710 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% CHX-based mouthrinse
Number of subjects: 16
Study 23138710 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 16
Study 20056649 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (2 g/d)
Number of subjects: 92
Study 20056649 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) (800 IU/d)
Number of subjects: 92
Study 20056649 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus Vitamin D(3)
Number of subjects: 92
Study 20056649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 18844764 — intervention group
Group type: EXPERIMENTAL
Intervention: Self blood pressure monitoring (SBPM)
Number of subjects: 578
Study 18844764 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitor possession
Number of subjects: 578
Study 16034227 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral baclofen
Number of subjects: 21
Study 16034227 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 21
Study 16034227 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 21
Study 14551096 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance therapy
Number of subjects: 56
Study 14551096 — intervention group
Group type: COMPARATOR
Intervention: Non-specific counselling
Number of subjects: 56
Study 10545429 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase 10+10-U double bolus (n=50)
Number of subjects: 126
Study 10545429 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (1.5 MU/60 min; n=10)
Number of subjects: 126
Study 10545429 — intervention group
Group type: COMPARATOR
Intervention: Accelerated alteplase (100 mg/90 min; n=21)
Number of subjects: 126
Study 10545429 — intervention group
Group type: COMPARATOR
Intervention: Conventional alteplase (100 mg/180 min; n=15)
Number of subjects: 126
Study 10545429 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase 10+5-U double bolus (n=15)
Number of subjects: 126
Study 10545429 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase 15-U single bolus (n=15)
Number of subjects: 126
Study 10545429 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 126
Study 10545429 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase (10+10 U) and streptokinase
Number of subjects: 126
Study 10545429 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 126
Study 9091371 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacrimal plug insertion in the inferior canaliculus
Number of subjects: 9
Study 9091371 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral eye without plug)
Number of subjects: 9
Study 1807971 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxapine
Number of subjects: 108
Study 1807971 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 108
Study 6318350 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi‐Profenid 150 mg (one 150 mg tablet twice daily for 2 days)
Number of subjects: 32
Study 6318350 — intervention group
Group type: COMPARATOR
Intervention: Conventional forms (two 50 mg Profenid capsules each morning and noon with one 100 mg suppository each evening for 2 days)
Number of subjects: 32
Study 6318350 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi‐Profenid 150 mg
Number of subjects: 32
Study 31835978 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet transfusion during rewarming phase (10 mL/kg)
Number of subjects: 46
Study 29731182 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus helveticus and Bifidobacterium longum)
Number of subjects: 110
Study 29731182 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic (galactooligosaccharide)
Number of subjects: 110
Study 29731182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 29731182 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic
Number of subjects: 110
Study 27731924 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaxial mini-incision (2.4 mm) phacoemulsification
Number of subjects: 20
Study 27731924 — intervention group
Group type: COMPARATOR
Intervention: Sleeveless microincision (1.1 mm) phacoemulsification
Number of subjects: 20
Study 25458091 — intervention group
Group type: EXPERIMENTAL
Intervention: Medullary canal saline irrigation
Number of subjects: 30
Study 25458091 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA without irrigation
Number of subjects: 30
Study 24443618 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab-based chemotherapy
Number of subjects: 114
Study 22527062 — intervention group
Group type: EXPERIMENTAL
Intervention: In-line filtration
Number of subjects: 807
Study 19686587 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional home-based exercise programme consisting of physical activity counselling, home-exercise programme, and exercise consultations.
Number of subjects: 90
Study 19686587 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional home-based exercise programme.
Number of subjects: 90
Study 17412737 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg at weeks 0, 2, 6, 14 and 22
Number of subjects: 28
Study 17412737 — intervention group
Group type: COMPARATOR
Intervention: Etanercept 25 mg twice weekly
Number of subjects: 28
Study 17412737 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 28
Study 17412737 — intervention group
Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 28
Study 17412737 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab and Etanercept
Number of subjects: 28
Study 15223109 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg)
Number of subjects: 49
Study 15223109 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 10963245 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management of oral anticoagulant therapy
Number of subjects: 50
Study 10963245 — intervention group
Group type: COMPARATOR
Intervention: Management by the anticoagulation clinic
Number of subjects: 50
Study 8640434 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral gentamicin
Number of subjects: 97
Study 8640434 — intervention group
Group type: COMPARATOR
Intervention: No intracameral antibiotics (control group)
Number of subjects: 97
Study 1531090 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (40 mg per day for 28 days)
Number of subjects: 61
Study 1531090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 6323525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir
Number of subjects: 63
Study 6323525 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 63
Study 6323525 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic acyclovir
Number of subjects: 63
Study 6323525 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody to gD and vp66
Number of subjects: 63
Study 31628930 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU intranasally)
Number of subjects: 38
Study 31628930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 29239664 — intervention group
Group type: EXPERIMENTAL
Intervention: SR paracetamol 2×1000 mg BID
Number of subjects: 676
Study 29239664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 676
Study 26980471 — intervention group
Group type: EXPERIMENTAL
Intervention: Necitumumab plus gemcitabine-cisplatin
Number of subjects: 1093
Study 26980471 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine-cisplatin
Number of subjects: 1093
Study 22512511 — intervention group
Group type: EXPERIMENTAL
Intervention: SCIP intervention
Number of subjects: 57
Study 20116153 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis dose
Number of subjects: 0
Study 20116153 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea kinetic modeling
Number of subjects: 0
Study 20116153 — intervention group
Group type: EXPERIMENTAL
Intervention: Different modalities of dialysis
Number of subjects: 0
Study 18991814 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 64
Study 18991814 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 64
Study 15520832 — intervention group
Group type: EXPERIMENTAL
Intervention: DraI polymorphism of the ADRA2A gene
Number of subjects: 177
Study 15520832 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype containing the less common allele of the DraI polymorphism
Number of subjects: 177
Study 12579017 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamically locked intramedullary hip screw (Group B)
Number of subjects: 80
Study 12579017 — intervention group
Group type: COMPARATOR
Intervention: Classically locked intramedullary hip screw (Group A)
Number of subjects: 80
Study 12579017 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group A and Group B)
Number of subjects: 80
Study 11109233 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery-rehearsal therapy (treatment group)
Number of subjects: 169
Study 11109233 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (control group)
Number of subjects: 169
Study 8845036 — intervention group
Group type: COMPARATOR
Intervention: Oral vaccination with whole cell/B subunit (CTB) cholera vaccine
Number of subjects: 14